Abstract:The 5% pre‐inserted PEG2000‐GSH PEGylated liposomal doxorubicin and PEGylated nanoliposomal doxorubicin connected to the spacer‐GSH targeting ligand (GSGGCE) and the PEG3400 was conducted using post‐insertion method. Next, biodistribution of the produced formulations was tested on healthy mice. Compared to the pre‐inserted formulation and Caelyx®, the post‐inserted formulations' concentration was lower in the heart and higher in brain tissues, resulting in boosting the brain concentration of accumulated doxorubicin with fewer possible side effects. Several obstacles limit the efficacy of brain tumour treatment, most notably the blood‐brain barrier (BBB), which prevents the brain uptake of the majority of accessible medicines due to tight junctions. The presence of glutathione (GSH) receptors on the BBB surface has been demonstrated in numerous papers; consequently, products containing glutathione as a targeting ligand coupled with nanoliposomes are used to enhance drug delivery across the BBB. Here, the 5% pre‐inserted PEG2000‐GSH PEGylated liposomal doxorubicin was conducted according to 2B3‐101 being tested in clinical trials. In addition, PEGylated nanoliposomal doxorubicin connected to the spacer‐GSH targeting ligand (GSGGCE) and the PEG3400 was conducted using post‐insertion method. Next, in vivo biodistribution of the produced formulations was tested on healthy mice to see if GSGGCE, as the targeted ligand, could cross the BBB compared to 5% pre‐inserted PEG2000‐GSH and Caelyx®. Compared to the pre‐inserted formulation and Caelyx®, the post‐inserted formulations' concentration was lower in the heart and higher in brain tissues, resulting in boosting the brain concentration of accumulated doxorubicin with fewer possible side effects, including cardiotoxicity. In comparison to the pre‐insertion procedure, the post‐insertion method is easier, faster, and more cost‐effective. Moreover, employing PEG3400 and the post‐insertion approach in the PEG3400‐GSGGCE liposomal formulations was found to be effective in crossing the BBB.

The role of glutathione conjugation on the transcellular transport process of PEGylated liposomes across the blood brain barrier

The comparison of biodistribution of glutathione PEGylated nanoliposomal doxorubicin formulations prepared by pre‐insertion and post‐insertion methods for brain delivery in normal mice

Glutathione transporter as a target for brain drug delivery

Elevated Cellular Uptake of Succinimide- and Glucose-Modified Liposomes for Blood–Brain Barrier Transfer and Glioblastoma Therapy

Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting.

Effect of size and pH-sensitivity of liposomes on cellular uptake pathways and pharmacokinetics of encapsulated gemcitabine

Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug

Transport of Nerve Growth Factor Encapsulated into Liposomes Across the Blood–brain Barrier: in Vitro and in Vivo Studies

Impact of PEGylation on biodistribution and tumor accumulation of Lipid-Mu peptide-DNA

Peptide-22 and Cyclic Rgd Functionalized Liposomes for Glioma Targeting Drug Delivery Overcoming Bbb and Bbtb

A Dual-Mediated Liposomal Drug Delivery System Targeting the Brain: Rational Construction, Integrity Evaluation Across the Blood-Brain Barrier, and the Transporting Mechanism to Glioma Cells

The influx/efflux mechanisms of D-peptide ligand of nAChRs across the blood-brain barrier and its therapeutic value in treating glioma

The Brain Targeting Mechanism of Angiopep-conjugated Poly(ethylene Glycol)-Co-poly(ɛ-caprolactone) Nanoparticles

Liposome Formulated with TAT-modified Cholesterol for Improving Brain Delivery and Therapeutic Efficacy on Brain Glioma in Animals

In Vitro and in Vivo Investigation of Glucose-Mediated Brain-Targeting Liposomes.

Targeted delivery of hybrid nanovesicles for enhanced brain penetration to achieve synergistic therapy of glioma

Increased Cellular Uptake of ApoE3- or c(RGD)-Modified Liposomes for Glioblastoma Therapy Depending on the Target Cells

Active Transportation of Liposome Enhances Tumor Accumulation, Penetration, and Therapeutic Efficacy

Transport of ginkgolides with different lipophilicities based on an hCMEC/D3 cell monolayer as a blood-brain barrier cell model

Stable Peptides Mediated Glioma Targeting Drug Delivery

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma